Allena Pharmaceuticals (ALNA) Stock Rating Reaffirmed by Wedbush

Wedbush reaffirmed their buy rating on shares of Allena Pharmaceuticals (NASDAQ:ALNA) in a report issued on Monday, December 18th. Wedbush also issued estimates for Allena Pharmaceuticals’ Q4 2017 earnings at ($0.28) EPS, Q1 2018 earnings at ($0.37) EPS, Q2 2018 earnings at ($0.37) EPS, Q3 2018 earnings at ($0.37) EPS, Q4 2018 earnings at ($0.37) EPS, FY2018 earnings at ($1.48) EPS, FY2019 earnings at ($1.88) EPS, FY2020 earnings at ($2.09) EPS and FY2021 earnings at ($2.59) EPS.

“We reiterate our Underperform rating and $37 price target post 3Q:17 and after speaking with management. We continue to see minimal value from Eagle’s pipeline and expect the company to acquire an asset.”,” the firm’s analyst wrote.

A number of other equities analysts have also recently issued reports on the stock. Cowen assumed coverage on shares of Allena Pharmaceuticals in a research report on Monday, November 27th. They issued an outperform rating on the stock. Jefferies Group initiated coverage on shares of Allena Pharmaceuticals in a research report on Monday, November 27th. They issued a buy rating and a $22.00 price objective on the stock. Finally, Credit Suisse Group initiated coverage on shares of Allena Pharmaceuticals in a research report on Monday, November 27th. They set an outperform rating and a $22.00 price target on the stock.

Allena Pharmaceuticals (NASDAQ:ALNA) traded up $0.06 during mid-day trading on Monday, hitting $10.24. 182,542 shares of the company’s stock were exchanged, compared to its average volume of 75,453. Allena Pharmaceuticals has a 12-month low of $8.66 and a 12-month high of $15.40. The company has a debt-to-equity ratio of -0.09, a quick ratio of 4.83 and a current ratio of 4.83.

In other Allena Pharmaceuticals news, Director James N. Topper acquired 500,000 shares of the business’s stock in a transaction on Monday, November 6th. The shares were acquired at an average price of $14.00 per share, for a total transaction of $7,000,000.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Bessemer Venture Partners Vii bought 36,000 shares of the company’s stock in a transaction dated Monday, November 6th. The stock was purchased at an average price of $14.00 per share, for a total transaction of $504,000.00. The disclosure for this purchase can be found here.

COPYRIGHT VIOLATION NOTICE: “Allena Pharmaceuticals (ALNA) Stock Rating Reaffirmed by Wedbush” was originally posted by The Lincolnian Online and is the property of of The Lincolnian Online. If you are reading this article on another website, it was stolen and republished in violation of U.S. and international copyright & trademark law. The legal version of this article can be viewed at https://www.thelincolnianonline.com/2018/01/13/wedbush-reiterates-buy-rating-for-allena-pharmaceuticals-alna-updated-updated.html.

Allena Pharmaceuticals Company Profile

Allena Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on developing and commercializing non-systemic oral protein therapeutics to treat metabolic and orphan diseases, with a particular focus on nephrologic and urologic conditions. Its lead product candidate, ALLN-177, is in an ongoing Phase II clinical trial and is being developed for the chronic management of hyperoxaluria and kidney stones.

Receive News & Ratings for Allena Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allena Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply